RavenQuest Raises $24.5 Million in Private Placements to Fund Bloomera Acquisition

RavenQuest Completes Financings for $24.5 Million

VANCOUVER, British Columbia, March 02, 2018 (GLOBE NEWSWIRE) —  RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) has completed the first tranche of its previously-announced brokered private placement (the “Brokered Placement”) of units (each, a “Unit”) and convertible debenture units (each, a “Debenture Unit”) of the Company, with Haywood Securities Inc. (“Haywood”) acting as lead agent.  In connection with completion of the Brokered Placement, the Company issued 3,581,300 Units at a price of $1.25 per Unit, and 15,000 Debenture Units at a price of $1,000 per Debenture Unit, for aggregate gross proceeds to the Company of $19,476,625.  The Company also completed a concurrent non-brokered private placement (the “Non-Brokered Placement” and, together with the Brokered Placement, the “Offering”) of 4,052,000 Units, for additional gross proceeds to the Company of $5,065,000.  The aggregate gross proceeds to the Company from the Offering was $24,541,625.

The closing of this financing represents an integral step toward closing the acquisition of RavenQuest’s first licensed facility. We are thrilled to see that both segments of the offering were oversubscribed, demonstrating the high-level of confidence that the market has in our company’s unique combination of innovation, strategic vision and execution.

George Robinson, Chief Executive Officer of the Company

RavenQuest is appreciative of this confidence and fully intends to surpass expectations as we continue our growth strategy throughout 2018 and beyond.  In addition, the oversubscription of this financing funds the construction of Alberta Green Biotech, our Edmonton facility which is scheduled for completion in mid-2018.  At this point, all of our 11,000-kilogram production capacity is fully funded.

Each “Unit” consists of one common share of the Company, and one common share purchase warrant (each, a “Warrant”).  Each Warrant is exercisable to acquire an additional common share of the Company at a price of $1.50 per a period of twenty-four months, subject to acceleration in the event that the closing price of the Company’s common shares on the Canadian Securities Exchange is greater than $2.75 for a period of ten consecutive trading days.

Each “Debenture Unit” consists of an unsecured convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 690 Warrants.  The Debentures are convertible at the option of the holder into common shares at a price of $1.45 per share, bear an interest rate of ten percent per annum and mature twenty-four months after the date of issue.

The proceeds of the private placement will be used by the Company to finance the acquisition of 8649081 Canada Inc. (“Bloomera”), and for general working capital purposes.  Bloomera is a licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations based in Markham, Ontario.  The acquisition of Bloomera is expected to close shortly.

In connection with the Brokered Placement, the Company paid a commission of $1,558,130, of which $932,952.50 was issued in Units at a deemed price per Unit of $1.25 and $625,117.50 was paid in cash, and issued to the Agent 1,178,090 compensation options (each, a “Compensation Option”). Each Compensation Option entitles the holder to acquire a common share of the Company at a price per common share of $1.25 for a period of twenty-four months from the closing of the Offering. As additional compensation, the Company paid to the Agent a corporate finance fee equal to $80,000 in the form of Units at a deemed issue price of $1.25 per Unit and issued to the Agent 64,000 corporate finance compensation options, having the same terms and attributes as the Compensation Options.

All securities issued in connection with the Offering are subject to a statutory four-month-and-one-day hold period, in accordance with applicable securities legislation.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About RavenQuest BioMed Inc.

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

Original Press Release

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter